1 Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines.

2 Evaluation of the Implementation of Additional Risk Minimization Activities in Europe, the USA, and Japan.

3 therapeutic interchange of parenteral anticoagulants: challenges for pharmacy and therapeutics committees

4 management of antithrombotic therapy during cardiac implantable device surgery

5 direct thrombin inhibitors prevent left atrial remodeling associated with heart failure in rats

6 marine diterpenes: molecular modeling of thrombin inhibitors with potential biotechnological application as an antithrombotic

7 evaluación del tripolifosfato de sodio como anticoagulante en determinaciones hematológicas en seres humanos assessment of anticoagulant sodium tripolyphosphate used in hematologic determinations in human being

8 Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?

9 Antiplatelets and Anticoagulants in Vitreoretinal Surgery: A Systematic Review.

10 Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis.

11 Thromboembolic, Bleeding, and Mortality Risks among Patients with Nonvalvular Atrial Fibrillation Treated with Dual Antiplatelet Therapy versus Oral Anticoagulants: A Population-Based Study.

12 Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter.

13 Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies.

14 Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.

15 Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.

16 How reliable is perioperative anticoagulant management? Determining guideline compliance and practice variation by a retrospective patient record review.

17 Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.

18 Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.

19 Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients

20 Corrigendum to “Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis” [Arch. Gerontol. Geriatr. 81 (March–April)(2019)209–214](S0167494318302450)(10.1016/j.archger.2018.12.013)

21 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis

22 Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis

23 Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis

24 Efficacy and safety of reduced-dose non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis of randomized controlled trials

25 Economic evaluation of the use of non-Vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: A modelling analysis using the healthcare system in the Netherlands

26 Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis

27 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis

28 Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis

29 Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis

30 Comment on “Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis”

31 Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

32 Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials

33 Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies

34 Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis

35 Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.

36 Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

37 Who will benefit from anticoagulant therapy? Use of the CHADS2 score and its variants

38 Synthesis, Antimicrobial, and Anticoagulant Activities of 2-(Arylsulfonyl)indane-1,3-diones

39 Who will benefit from anticoagulant therapy? Use of the CHADS2 score and its variants

40 Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

41 Low-Intensity Shockwave Therapy (LiST) for Erectile Dysfunction: Is It Safe for Patients on Anticoagulant Medication?

42 Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.

43 Resistance to anticoagulant rodenticides in Martinique could lead to inefficient rodent control in a context of endemic leptospirosis.

44 Development and Assessment of RecosDoc-MTeV to Improve the Quality of Direct Oral Anticoagulant Prescription for Venous Thromboembolic Disease.

45 Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

46 The perioperative management of direct oral anticoagulants, a single center observational study

47 Direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.

48 Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.

49 Pharmacogenomics of 4-hydroxycoumarin anticoagulants

50 Letter by Govindarajan and Salgado regarding article, "risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial"

51 Use of oral anticoagulants after ischaemic stroke in patients with atrial fibrillation and cancer.

52 Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?

53 Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?

54 caracterizaÇÃo e atividade anticoagulante de polissacarÍdeos sulfatados extraÍdos da alga marrom dictyopteris justii

55 indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients

56 heterofucans from the brown seaweed canistrocarpus cervicornis with anticoagulant and antioxidant activities

57 anticoagulante e opinião pessoal da autoridade: ambas, um risco certo versus um benefício incerto?

58 modern approaches to anticoagulant therapy during catheter ablation treatment of non-valvular atrial fibrillation

59 heparina e k3edta como anticoagulantes para tambaqui (colossoma macropomum cuvier, 1816) heparin and k3edta as anticoagulants for tambaqui (colossoma macropomum cuvier, 1816)

60 current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism

61 newer anticoagulants and their impact on interventional pain procedures

62 anticoagulant-induced hemopericardium with tamponade: a case report and review of the literature

63 infartos cerebrais em pacientes jovens relacionados a deficiência de anticoagulantes naturais proteína c e proteína s protein c and s deficiencies related stroke in young patients

64 non-vitamin k antagonist oral anticoagulants vs. warfarin at risk of fractures: a systematic review and meta-analysis of randomized controlled trials

65 anticoagulant therapy in patients with non-valvular atrial fibrillation: drug choice and dosage adjustment

66 hematoma subdural de medula espinhal associada ao uso de anticoagulante oral hematoma subdural de la médula espinal asociado al uso de anticoagulante oral spine subdural hematoma: a rare complication associated with vitamin k antagonist (vka)

67 atrial sensor, remote monitoring and new anticoagulant drugs: identification and treatment of a patient with unknown and asymptomatic atrial flutter

68 practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants

69 the new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy

70 terapia anticoagulante en fibrilación auricular

71 non-traumatic intramural hematomas in patients on anticoagulant therapy: report of three cases and overview of the literature

72 structural analysis and anticoagulant activities of the novel sulfated fucan possessing a regular well-defined repeating unit from sea cucumber

73 anticoagulant therapy in everyday clinical practice: data of the retrospective cross-sectional study

74 use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence

75 prevention of thromboembolic complications in atrial fibrillation - rat poison or new oral anticoagulants: do we have a choice, and should we be afraid to make it? first clinical experience with rivaroxaban in nizhny novgorod

76 nonvitamin k antagonist oral anticoagulants (noacs): the tide continues to come in

77 application of thrombin powder after tooth extraction in patients receiving anticoagulant therapy

78 new anticoagulant strategies in st elevation myocardial infarction: trials and clinical implications

79 cumarinas, interacción con anticoagulantes antagonistas de la vitamina k y seguridad del haba tonka coumarins: interaction with vitamin k antagonists and safety of tonka bean

80 Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.

81 [Efficiency of the Decision-Making Module in the Personalized Choice of an Anticoagulant].

82 Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study

83 DNA-Programmed Gold Nanoparticles for Precision Delivery of a Tissue Plasminogen Activator and Thrombin Inhibition in Thrombolytic and Anticoagulant Therapy.

Keyword Connections

Journals

Research Groups

Bibliographies